Disparities in urologic care and how telemedicine can help mitigate them
Urologist Adam J. Gadzinski, MD, MS, shares how telemedicine can help improve access to urologic care.
How has the COVID-19 pandemic presented challenges in conducting clinical trials?
Angela B. Smith, MD, MS, discusses how her institution has adjusted how it conducts clinical trials in the COVID-19 era.
Dr. Vikram M. Narayan on subgroup analyses of nadofaragene firadenovec in NMIBC
The analyses are from a pivotal phase 3 trial of nadofaragene firadenovec which previously met its primary end point of complete response.
Management of high-risk NMIBC: Options for treatment expand
“As urologists, we all need to start speaking in risk stratification criteria,” says Katie Murray, DO.
Jelmyto for low-grade UTUC: Clinical experience and side effects to watch for
Angela B. Smith, MD, MS, describes her institution’s early clinical experience with mitomycin-containing reverse thermal gel (Jelmyto).
Dr. Katie Murray on the challenges of treating low-grade UTUC
Murray also discusses the low-grade upper tract urothelial cancer treatment mitomycin-containing reverse thermal gel (Jelmyto).
Dr. Declan G. Murphy on results of the proPSMA study of Ga 68 PSMA-11 in prostate cancer
Dr. Declan G. Murphy discusses results from the phase 3 proPSMA study of Ga 68 PSMA-11 in patients with high-risk prostate cancer.
Pembrolizumab for first-line mRCC: Anecdotal evidence in real-world setting
Arjun V. Balar, MD, discusses combination treatment with pembrolizumab (Keytruda) and axitinib (Inlyta) in the first-line setting for metastatic RCC.
Dr. Surena Matin discusses significance of OLYMPUS trial, Jelmyto
“[Low-grade upper tract urothelial carcinoma] is fairly uncommon, yet it’s common enough that every urologist comes across it,” says Surena F. Matin, MD.
